Skip to main content
Journal cover image

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.

Publication ,  Journal Article
Chan, A; Verma, S; Loibl, S; Crawford, J; Choi, MR; Dreiling, L; Vandenberg, T
Published in: Crit Rev Oncol Hematol
February 2012

In this article, we reviewed and quantified reporting of the risk of myelotoxicity, specifically febrile neutropenia (FN), and the related use of supportive care with colony-stimulating factor (CSF) or antibiotics in clinical trials published between January 2005 and June 2009, evaluating emerging regimens for the treatment of selected solid tumors. Our analysis showed that clinically significant neutropenia and neutropenia-related events were generally described in the studies evaluated (grade 3/4 neutropenia incidence, 72%; FN incidence, 53%). However, use of CSF and antibiotics was infrequently and inconsistently reported (trials reporting prophylactic CSF and antibiotics use: in the methods section, 38% and 10%, respectively; in the results section, 19% and 1%, respectively). These results highlight the need for a standardized approach to reporting neutropenic outcomes and use of supportive care measures. This can assist clinicians in prospectively managing relevant toxicities associated with these emerging regimens and thereby facilitate their safe and effective use in clinical practice.

Duke Scholars

Published In

Crit Rev Oncol Hematol

DOI

EISSN

1879-0461

Publication Date

February 2012

Volume

81

Issue

2

Start / End Page

136 / 150

Location

Netherlands

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasms
  • Humans
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chan, A., Verma, S., Loibl, S., Crawford, J., Choi, M. R., Dreiling, L., & Vandenberg, T. (2012). Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol, 81(2), 136–150. https://doi.org/10.1016/j.critrevonc.2011.03.003
Chan, Arlene, Shailendra Verma, Sibylle Loibl, Jeffrey Crawford, Mi Rim Choi, Lyndah Dreiling, and Ted Vandenberg. “Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.Crit Rev Oncol Hematol 81, no. 2 (February 2012): 136–50. https://doi.org/10.1016/j.critrevonc.2011.03.003.
Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, et al. Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 2012 Feb;81(2):136–50.
Chan, Arlene, et al. “Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.Crit Rev Oncol Hematol, vol. 81, no. 2, Feb. 2012, pp. 136–50. Pubmed, doi:10.1016/j.critrevonc.2011.03.003.
Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T. Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 2012 Feb;81(2):136–150.
Journal cover image

Published In

Crit Rev Oncol Hematol

DOI

EISSN

1879-0461

Publication Date

February 2012

Volume

81

Issue

2

Start / End Page

136 / 150

Location

Netherlands

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasms
  • Humans
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology